What Are Research Peptides?

A peptide is a chain of amino acids joined by amide bonds. Each amino acid contributes an amino group, a carboxyl group, and a side chain that gives it its character. When the carboxyl group of one residue condenses with the amino group of the next, a molecule of water is released and an amide bond forms. In this context that bond is called a peptide bond, and the amino acids incorporated into the chain are called residues.

Every peptide has direction. One end retains a free amino group and is called the N-terminus. The other retains a free carboxyl group and is called the C-terminus. By universal convention, sequences are written N-terminus first. The sequence GHK means glycine at the N-terminus, then histidine, then lysine at the C-terminus. Reading it in the other direction describes a different molecule.

The peptide bond has partial double bond character from resonance, which makes it planar and restricts rotation. That constraint, plus hydrogen bonding between backbone atoms, lets even short chains adopt preferred conformations rather than behaving as free-flowing strings.

Side chains determine nearly everything practical. Lysine, arginine, and histidine carry positive charge at physiological pH, aspartate and glutamate negative. Leucine, valine, and phenylalanine are hydrophobic. Cysteine forms disulfide bridges, methionine oxidizes, asparagine deamidates. Composition predicts solubility, chromatographic behavior, and stability, which is why the sequence is the first thing to read when planning how to handle a new compound.

The boundaries are conventions rather than natural laws, but they are used consistently enough to be worth stating.

A single amino acid is a monomer. Two joined together form a dipeptide, three a tripeptide, and so on. Chains of roughly two to twenty residues are commonly called oligopeptides, and chains up to about fifty residues are called polypeptides. Above roughly fifty residues, or above about five to ten kilodaltons, the term protein is generally used.

The functional distinction is more useful than the numeric one. Proteins typically fold into a defined three-dimensional structure essential to their function, and denaturing it destroys the function. Short peptides usually lack a single dominant fold in free solution and often adopt structure only on binding a target. So peptides tolerate lyophilization and organic solvents better than proteins, and their stability problems tend to be chemical rather than conformational.

Synthesis route follows the same divide. Chains up to roughly fifty residues are made by chemical synthesis. Longer chains are usually produced recombinantly, because stepwise chemical synthesis accumulates errors as length increases.

The dominant method is solid phase peptide synthesis, introduced by Bruce Merrifield in 1963, a contribution recognized with the Nobel Prize in Chemistry in 1984. The concept is to anchor the growing chain to an insoluble resin bead so that excess reagents and byproducts can be washed away at every step rather than requiring purification between steps.

The modern standard is Fmoc chemistry. The first amino acid is attached to the resin through its C-terminus, with its alpha-amino group protected by a fluorenylmethyloxycarbonyl group and its side chain protected by an orthogonal group. Synthesis then proceeds in cycles. The Fmoc group is removed with piperidine, the resin is washed, the next amino acid is activated with a coupling reagent and introduced in excess, coupling proceeds, and the resin is washed again. Each cycle adds one residue, and the chain is built from C-terminus toward N-terminus, the opposite direction from ribosomal synthesis.

At the end, the peptide is cleaved from the resin and its side chain protecting groups are removed, usually in one step with a trifluoroacetic acid cocktail containing scavengers such as triisopropylsilane and water to trap the reactive cations released. The crude peptide is precipitated in cold ether and purified by preparative reverse-phase HPLC on a C18 column, and fractions meeting specification are pooled and lyophilized to a dry cake.

This is where the impurity profile originates. No coupling step is perfectly efficient, so a fraction of chains fail to extend at each cycle, producing deletion sequences. Incomplete deprotection leaves protecting groups attached, scavenger adducts form, and cleavage conditions can oxidize methionine or racemize sensitive residues. Because purification uses TFA-containing mobile phases, the product is generally recovered as a trifluoroacetate salt with one counterion per basic site. Purity is not an abstract property. It is the residue of a specific manufacturing process, which is why the analytical documentation exists.

Peptides occupy a chemical space between small molecules and biologics, and that position is what makes them interesting as research tools.

Endogenous signaling in living systems runs substantially on peptides. Hormones, neuropeptides, growth factors, and immune mediators are frequently peptidic, and they act through receptors with high specificity. A synthetic peptide that reproduces or modifies such a sequence is therefore a precise probe for a specific pathway, in a way that a broadly acting small molecule usually is not. That selectivity is the primary scientific attraction, and it is why so much peptide research is mechanistic rather than therapeutic in character.

There are structural reasons too. Peptides present a larger binding surface than a typical small molecule, which makes them candidates for protein-protein interfaces, and because they are synthesizable in defined sequence, analogues can be made systematically to map structure-activity relationships one residue at a time.

The limitations are equally well characterized. Peptides are substrates for the proteases abundant in biological fluids, so persistence is often short. They are poorly absorbed across membranes. Longer sequences can provoke immune responses. And a great deal of peptide research remains at the in vitro and animal model stage, never having been tested in humans at all.

Research use only, abbreviated RUO, is a regulatory category, not a marketing disclaimer. It describes a product supplied for laboratory investigation and not evaluated or authorized for any other purpose.

An RUO compound has not been approved as a drug by the United States Food and Drug Administration or any comparable authority. No regulatory body has reviewed evidence of safety or efficacy for it, no approved conditions of use exist, and no pharmaceutical manufacturing standard has been applied. It is also not a dietary supplement: under the Federal Food, Drug, and Cosmetic Act, an article authorized for investigation as a new drug and made the subject of substantial public clinical investigations is excluded from the supplement definition, and FDA has stated that various peptides fall outside that category on this and other grounds. It is not a diagnostic product either, since in vitro diagnostic claims require their own pathway.

So RUO material is supplied for laboratory research use only, not for human or veterinary use, not for consumption, not for diagnostic use. That is a description of the product's actual regulatory status, and nothing about a certificate of analysis changes it. A COA reports identity and purity, which are chemistry questions, and has no bearing on whether a compound has been evaluated for safety in any organism.

Several distinct regimes intersect around research peptides, and they are frequently conflated in public discussion.

The drug approval pathway is the first. To market a peptide for a medical use in the United States, a sponsor must complete preclinical work, file an investigational new drug application, run clinical trials, and obtain approval. Some peptides have completed that path. The overwhelming majority of compounds discussed as research peptides have not entered it at all.

Compounding is the second. In 2023 FDA categorized several peptides, including BPC-157, into Category 2 of its bulk drug substances review for section 503A compounding, a designation applied to substances for which the agency identified significant safety risks. That action concerns what compounding pharmacies may use and does not create a research restriction, but it is a clear signal about the state of the safety evidence for those specific compounds.

Dietary supplement law is the third. FDA has issued warning letters to firms marketing peptides as supplements, on the basis that the articles do not meet the statutory definition of a dietary ingredient or fall under the exclusionary clause described above. Marketing a research peptide for human consumption is therefore not a gray area.

Anti-doping rules are a fourth, separate regime. The World Anti-Doping Agency prohibited list includes numerous peptide classes, and inclusion is independent of whether a compound is approved anywhere. Import and export controls form a fifth layer, since international shipment of research chemicals is subject to customs rules that vary by country.

Most confusion about research peptides comes from flattening very different kinds of evidence into a single claim. A disciplined reader keeps the tiers separate.

In vitro work, meaning cells or isolated proteins in culture, establishes that a molecule can do something under controlled conditions at chosen concentrations. It is where mechanism is worked out, and it is the weakest evidence for what happens in an organism, because concentration, exposure duration, and cellular context are all set by the experimenter.

Animal model work adds a whole organism with intact physiology, and it is where most of the published literature on research peptides sits. It is genuinely informative about mechanism and about gross effects, and it translates to humans inconsistently. Species differences in metabolism, receptor distribution, and disease modeling are substantial, and the history of drug development contains many compounds with excellent rodent data that failed entirely in human trials.

Human clinical data is a different tier again, and within it a small early phase study is not equivalent to a large randomized controlled trial with a prespecified endpoint. For most compounds sold as research peptides, this tier is simply empty. When it is empty, the honest statement is that the compound has not been studied in humans, not that it is promising or that human data is forthcoming.

A few practical habits close the gap, and one of them is easy to overlook: impurity profiles vary between suppliers, so a failure to replicate can reflect the material as easily as the biology.